dual glp 1 and gip receptor agonist This review summarizes how GLP-1 GIP/GLP-1 agonists act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based Dual GLP-1/GIP Agonist | Tirzepatide

Learn how GLP-1 receptor agonists help patients with type 2 diabetes and obesity manage blood sugar, lose weight, and protect heart health.

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Discover how GLP-1RAs reduce external eating behavior and improve appetite and glucose control in people with type 2 diabetes.

The airball comes as Novo scrambles to regain a majority share of the GLP-1 market.

Learn how low-dose semaglutide and tirzepatide may support metabolism, menopause, inflammation, and autoimmune health.